Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

COMPLETED RESEARCH: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CT10

Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Clinical Trials, Leukemia, Lymphoma

Presenter: Nilanjan Ghosh, MD, PhD, Chief, Lymphoma Division, Levine Cancer Institute, Atrium Health, Charlotte, NC

Co-Authors: Jacqueline C. Barrientos, MD, MS, Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY; Jeff P. Sharman, MD, Willamette Valley Cancer Institute & Research Center, Eugene, OR; Danielle Brander, MD, Duke University Health System, Durham, NC; Meghan Gutierrez, Lymphoma Research Foundation, New York, NY; Karen Kadish, APRN-BC, MSN, OCN, Tufts Medical Center, Boston, MA; Israel Arango Hisijara, MD, Pharmacyclics, an AbbVie Company, Sunnyvale, CA; Sandhya Upasani, MS, Pharmacyclics, an AbbVie Company, Sunnyvale, CA; Jennifer Han, PharmD, Janssen Scientific Affairs, Horsham, PA; Qing Huang, Janssen Scientific Affairs, Horsham, PA; Reethi Iyengar, PhD, Pharmacyclics, an AbbVie Company, Sunnyvale, CA; Anthony R. Mato, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Background: The informCLL registry is the largest prospective, US-based observational registry of patients who received treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the era of novel agents.

Objective: To report baseline characteristics, prognostic biomarker testing, and treatment patterns in routine clinical practice for patients enrolled in the informCLL registry.

Methods: From October 2015 to June 2019, the informCLL registry enrolled eligible patients aged ≥18 years with CLL or SLL who had initiated FDA-approved treatment for CLL or SLL within ≥45 days of enrollment. Based on the index treatment at enrollment, patients were classified into 5 groups: ibrutinib (single-agent or combination), chemoimmunotherapy, chemotherapy, immunotherapy, and other novel agents.

Results: The informCLL registry enrolled 1461 patients; 855 (59%) patients were treatment-naïve and 606 (41%) had relapsed or refractory disease; the median age was 71 years, 64% of the patients were male, and 88% had ECOG performance status of 0/1. For patients with staging performed (N = 852), 51% had Rai stage III/IV. Most (93%) enrolling sites were community-based practices. The median time from diagnosis to index treatment for untreated patients was 18.6 months and 84.27 months for patients with relapsed or refractory disease. The median follow-up was 14.9 months for untreated patients and 15.3 months for patients with relapsed or refractory disease. Overall, prognostic biomarker testing was infrequent: fluorescence in situ hybridization testing was performed in 28% of patients, testing for TP53 mutation in 11%, and testing for IGHV mutation was 12%. Of patients who had prognostic biomarker testing, 24% (100/415) had deletion 17p, 27% (43/162) had TP53 mutation, and 71% (121/171) had wild-type IGHV. Overall, the most common treatment was ibrutinib (46%), and 87% started ibrutinib at the recommended dose of 420 mg daily. For patients continuing ibrutinib therapy, 75% did not require dose modifications. At 12 months or 24 months, 77% (307/401) and 68% (126/184) of patients continued ibrutinib therapy, respectively. For patients who completed chemoimmunotherapy regimens, bendamustine plus rituximab (BR) and fludarabine, cyclophosphamide, and rituximab (FCR) were the most common chemoimmunotherapy regimens received; 80% and 85% of patients who received BR and FCR, respectively, received <6 cycles. Only 6% of patients had index treatment of other novel agents.

Conclusion: Results from the informCLL registry allow for a prospective assessment of CLL treatment patterns in the era of novel agents. Ibrutinib was the most common index treatment received, and most ibrutinib-treated patients continued therapy at 2 years of follow-up; 33% of patients received chemoimmunotherapy. Prognostic biomarker testing was infrequent, especially for TP53 and IGHV mutational status, indicating that prognostic marker testing results may not always guide treatment selection for patients with high-risk disease.

Related Items
Comparing Cyclophosphamide-Based versus Etoposide-Based Chemomobilization for Autologous Hematopoietic-Cell Transplant in Patients with Lymphoma
Taylor Dennison, PharmD, Zachary Pedretti, PharmD, Jing Zhu, PharmD, Kurtis Stocker, PharmD, Ryan Shaw, PharmD, Tatjana Grgic, PharmD, Maurice Alexander, PharmD, Marcie Riches, MD, MS, Hillary Heiling, BS, Jonathan Ptachcinski, PharmD
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in Original Article, Transplant, Lymphoma
Yescarta First CAR T-Cell Therapy Approved for Follicular Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in From the Literature, Leukemia
Vyxeos Now Indicated for Pediatric Patients with AML
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Leukemia, Pediatric Cancer
Ukoniq, New Targeted Therapy, FDA Approved for Marginal-Zone and Follicular Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers
Operation Angel on the Line: Oncology Pharmacist and Pharmacy Students Piloting a New Oral Chemotherapy Telehealth Clinic During the COVID-19 Pandemic
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy, COVID-19
Integration of a Clinical Pharmacist in a Phase 1 Clinical Trial Program
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials
Feasibility and Perceived Benefit of an Oral Chemotherapy Pharmacy Monitoring Program to Assess Symptom Burden and Medication Adherence in Patients with Cancer
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy, Oncology Pharmacy Protocols
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.